Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA , both in Circulating Tumor Cells and in plasma (cell-free circulating tumor DNA). The Company's mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Biocept utilizes patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, the Company offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. Biocept's strategic focus is to promote its unique technology (CEE, cell enrichment and extraction) and family of laboratory tests (OncoCEE) to the Oncology Community. 

The CEE system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells in patients with early-stage, metastatic or recurrent cancers. Biocept provides products and services to detect and analyze these rare cells in order to provide information that physicians can use to make treatment decisions. The Company employs its unique laboratory tests through an offering of services to medical/surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical/clinical researchers.

Show more

Employee Rating

3.1More
TypePublic
HQSan Diego, US
Founded1993
Size (employees)42 (est)
Websitebiocept.com
Biocept was founded in 1993 and is headquartered in San Diego, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Biocept

Michael W. Wallace

Michael W. Wallace

President & CEO
Lyle Arnold

Lyle Arnold

Svp & CSO
Show more

Biocept Office Locations

Biocept has an office in San Diego
San Diego, (HQ)
5810 Nancy Ridge Dr
Show all (1)
Report incorrect company information

Biocept Financials and Metrics

Biocept Revenue

Biocept's revenue was reported to be $5.07 m in FY, 2017
USD

Revenue (Q3, 2018)

761.6k

Gross profit (Q3, 2018)

(1.7m)

Gross profit margin (Q3, 2018), %

(225.9%)

Net income (Q3, 2018)

(6.7m)

EBIT (Q3, 2018)

(6.0m)

Market capitalization (4-Dec-2018)

4.8m

Closing stock price (4-Dec-2018)

1.2

Cash (30-Sep-2018)

9.0m
Biocept's current market capitalization is $4.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.1m

Cost of goods sold

4.6m6.9m9.3m

Gross profit

(4.3m)

Gross profit Margin, %

(84%)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.4m8.8m4.6m2.1m

Accounts Receivable

10.6k34.2k129.0k1.2m

Inventories

338.7k435.9k484.6k498.7k

Current Assets

5.9m9.6m5.8m4.3m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(15.9m)(16.9m)(18.4m)(21.6m)

Depreciation and Amortization

251.2k261.4k322.0k575.7k

Inventories

(401.4k)(80.4k)494.7k100.9k

Accounts Payable

(981.9k)(51.8k)332.7k349.9k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.1m)(8.1m)(12.0m)

Depreciation and Amortization

57.7k112.2k177.5k

Inventories

(3.5k)(41.8k)(46.2k)412.9k

Accounts Payable

(830.7k)(865.6k)(992.4k)970.5k612.5k766.4k853.3k946.3k1.7m1.4m1.8m1.6m
USDY, 2018

Financial Leverage

1.6 x
Show all financial metrics
Report incorrect company information

Biocept Online and Social Media Presence

Embed Graph
Report incorrect company information

Biocept News and Updates

Biocept Reports Third Quarter 2018 Financial Results

SAN DIEGO, Nov. 13, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and nine...

Biocept to Release Third Quarter 2018 Financial Results and Host Investor Conference Call on November 13, 2018

SAN DIEGO, Nov. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release...

Circulating Tumor Cell Diagnostics Global Market 2018 Top Key Players – Janssen Diagnostics , Advanced Cell Diagnostics , Aviva Biosciences , Biocept Inc , Biofluidica Inc. , CellTraffix Inc. , Clearbridge BioMedics Pte Ltd and Forecast to 2023wdxefcqufszuzezftuxetqsqxt

Wiseguyreports.Com Added New Market Research Report On -“Circulating Tumor Cell Diagnostics Market 2018 Key Players, Applications and Future Demand Forecast to 2023 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Circulating Tumor Cell Diagnostics Global Market 2018 Top Key Players – Janssen Diagnostics , Advanced Cell Diagnostics , Aviva Biosciences , Biocept Inc , Biofluidica Inc. , CellTraffix Inc. , Clearbridge BioMedics Pte Ltd and Forecast to 2023

Wiseguyreports.Com Added New Market Research Report On -“Circulating Tumor Cell Diagnostics Market 2018 Key Players, Applications and Future Demand Forecast to 2023 ”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Biocept to Present at the Dawson James Securities Small Cap Growth Conference on October 30

SAN DIEGO, Oct. 23, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO...

Liquid Biopsy 2018 Global Market Key Players – Biocept, Qiagen, Roche Diagnostics, Bio-Rad Laboratories, Myriad Genetics, Menarini-Silicon Biosystems – Analysis and Forecast to 2023

WiseGuyRerports.com Presents “Global Liquid Biopsy Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023” New Document to its Studies Database Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information

Biocept Company Life and Culture

Report incorrect company information

Biocept Frequently Asked Questions

  • When was Biocept founded?

    Biocept was founded in 1993.

  • Who are Biocept key executives?

    Biocept's key executives are Michael W. Wallace and Lyle Arnold.

  • How many employees does Biocept have?

    Biocept has 42 employees.

  • What is Biocept revenue?

    Latest Biocept annual revenue is $5.1 m.

  • What is Biocept revenue per employee?

    Latest Biocept revenue per employee is $120.7 k.

  • Who are Biocept competitors?

    Competitors of Biocept include VolitionRX, Arrogene and NantOmics.

  • Where is Biocept headquarters?

    Biocept headquarters is located at 5810 Nancy Ridge Dr, San Diego.

  • Where are Biocept offices?

    Biocept has an office in San Diego.

  • How many offices does Biocept have?

    Biocept has 1 office.